N790.F LIR Life Sciences Corp.

Healthcare Biotechnology Frankfurt Exchange
0.0670 EUR
Close of Nov 12, 2026
0.0470 1.58
Market cap
EUR 1.92M
P/E
-
P/B
54.02x
ROE
-5,634.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jul 2026.

Is N790.F undervalued?

Graham number

The Graham number of LIR Life Sciences Corp. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

LIR Life Sciences Corp. fundamental analysis

No fundamental analysis for LIR Life Sciences Corp. yet.

LIR Life Sciences Corp. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About LIR Life Sciences Corp.

LIR Life Sciences Corp. operates as biopharmaceutical company that develops transdermal delivery system through formulations of GLP-1 combination therapies for obesity and metabolic disorders. The company is based in Vancouver, Canada.

Full company profile